Rheumatoid arthritis: New developments in the use of existing therapies

J. R. O'Dell, D. L. Scott

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Combination therapy with methotrexate may be the newest standard to which future therapies for rheumatoid arthritis are compared. Many questions remain to be answered regarding the appropriateness of such combination therapies for specific patients and clinical situations, and the optimal therapeutic combinations. Other unanswered questions regarding combination therapy include the need for appropriate monitoring, long-term safety and cost-benefit implications. Future research is needed to clarify the role of biological response modifiers (e.g. anti-tumour necrosis factor therapies) and matrix metalloproteinase inhibitors, both as components of and alternatives to methotrexate combination regimens.

Original languageEnglish (US)
Pages (from-to)24-26
Number of pages3
Issue numberSUPPL. 2
StatePublished - Nov 1999


  • Biological response modifiers
  • Combination therapy
  • Cyclosporin
  • Hydroxychloroquine
  • Leflunomide
  • Metalloproteinase inhibitors
  • Methotrexate
  • Sulphasalazine

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)


Dive into the research topics of 'Rheumatoid arthritis: New developments in the use of existing therapies'. Together they form a unique fingerprint.

Cite this